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Dear Sir,
Following the publication of our study entitled “Meta-
analysis of the performance of
18F-FDG PET in cutaneous
melanoma” in the February 2010 issue [1], we reply to the
comments presented in the above letter to the editor.
First, as described in the “Materials and methods”
section, we performed a systematic search of the literature
to identify relevant studies published between January 2000
and January 2006. Then, the meta-analysis was performed
and the manuscript was prepared for publication. Finally, it
was accepted for publication in 2009. Because of this 3-
year delay between the literature search and publication,
studies published after January 2006 were not included. The
delay between the presentation of results as abstracts and full
publication of results has been previously studied in the meta-
analysis published by Scherer et al. [2]. In this meta-analysis,
most studies were published in full within 2 years of their
appearance as abstracts, although some studies presented a
delay of up to 3 years. However, the results of our meta-
analysis may be updated to include the most recent studies.
Second, the methodological quality criteria applied in our
meta-analysis had been developed and applied in previous
meta-analyses by Huebner et al. [3], Gould et al. [4],
Delgado-Bolton et al. [5] and Schwimmer et al. [6]. These
methodological quality criteria were developed to systemat-
ically analyse studies focusing on the performance of
18F-
FDG PET. They apply 7 guidelines which include 38 items,
in order to extensively evaluate the methodological quality of
the studies and, also, establish guidelines for carrying out
methodologically rigorous studies. These criteria are based
on evidence-based medicine criteria and, to the best of our
knowledge, are not biased. Regarding the quality assessment
of studies of diagnostic accuracy included in systematic
reviews (QUADAS) criteria [7, 8], which is a 14-item
instrument, it can be useful for the assessment of diagnostic
accuracy studies and, if used extensively, it will facilitate
comparison among meta-analyses. However, the QUADAS
tool has not been designed specifically for
18F-FDG PET. As
evidenced in the meta-analysis by Kwee et al. [9], the
QUADAS criteria present certain limitations when analysing
18F-FDG PET diagnostic accuracy studies. These authors
eliminated 3 of the 14 criteria and added another different
one. This indicates that the QUADAS criteria may not be the
optimal tool for evaluating the methodological quality in
18F-
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criteria applied in our meta-analysis include certain
guidelines and items not analysed or incomplete in the
QUADAS criteria, such as: description of study design
and patient selection criteria, characteristics of patient
population finally studied, sensitivity and specificity
data, and change in management information. These
additional aspects not included in the QUADAS criteria
can be of relevance when assessing the methodological
quality and establishing guidelines for performing meth-
odologically rigorous studies on
18F-FDG PET.
Third, regarding the end-points chosen for our meta-
analysis, it would have been very interesting to analyse the
diagnostic performance of
18F-FDG PET depending on the
American Joint Committee on Cancer (AJCC) stage.
Unfortunately, most of the original papers did not supply
enough information on the AJCC stage of the patients
included. Many studies included heterogeneous populations
regarding the AJCC stage and the results of the
18F-FDG
PET were not presented independently for each AJCC
stage. Therefore, it was not possible to study this end-point.
If future studies include enough details of population
characteristics and present the results of sensitivity and
specificity for each subgroup of patients, it will be possible
to analyse this end-point in a meta-analysis.
Fourth, in our meta-analysis the quantitative analysis
evaluated subgroups of studies that presented the same
method of counting findings (patients, lesions, basins, etc.).
We separately analysed like data (patients, lesions, basins,
lymph nodes, areas or scans), because we considered the
results of studies that referred to different data (patients,
lesions, basins, etc.) not comparable. Because of this, the
pooled data were reduced. However, we considered it
methodologically more rigorous than pooling together
different data.
Finally, we agree with the comment regarding the need
for standardization in the reporting of studies to improve
the information provided by each individual study, which
will allow future meta-analyses and cost-effectiveness
analyses to establish the role of
18F-FDG PET.
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